Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Phesgo via Syringe vs OBDS
NCT05275010Phase 1Completed
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoints: Area Under the Time-Concentration Curve From the Start of Dosing to 63 Days for Serum Pertuzumab, Area Under the Time-Concentration Curve From the Start of Dosing to 63 Days for Serum Trastuzumab and 2 more. Started May 2022; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05275010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275010.